Changes to the Code
S. 4332 · Medication Competition Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 262 Regulation of biological products
3 changes the bill asks for here, 3 carried out
- Carried out:
by inserting
determine any applicable exclusivity period under paragraph (6) or (7), and shall
afterthe Secretary shall
; - Carried out:
by striking the period at the end and inserting
, as follows:
; and - Carried out:
by adding at the end the following:
(I) Exclusivity for first interchangeable biological products.— (aa) Products licensed on or after the date of enactment.— With respect to a biological product licensed under this subsection on or after the date of enactment of the Medication Competition Act, the Secretary shall …
§ 262(k)(9)Public listing(A)–(B)
Start of § 262 to (k)(9)(A)(ii) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (A)(iii) | (iii) Patent information | (iii) Patent information | ||
| Not later than 30 days after a list of patents under subsection (l)(3)(A), or a supplement to such list under subsection (l)(7), has been provided by the reference product sponsor to the subsection (k) applicant respecting a biological product included on the list published under this subparagraph, the reference product sponsor shall provide such list of patents (or supplement thereto) and their corresponding expiry dates to the Secretary, and the Secretary shall, in revisions made under clause (ii), include such information for such biological product. Within 30 days of providing any subsequent or supplemental list of patents to any subsequent subsection (k) applicant under subsection (l)(3)(A) or (l)(7), the reference product sponsor shall update the information provided to the Secretary under this clause with any additional patents from such subsequent or supplemental list and their corresponding expiry dates. | Not later than 30 days after a list of patents under subsection (l)(3)(A), or a supplement to such list under subsection (l)(7), has been provided by the reference product sponsor to the subsection (k) applicant respecting a biological product included on the list published under this subparagraph, the reference product sponsor shall provide such list of patents (or supplement thereto) and their corresponding expiry dates to the Secretary, and the Secretary shall, in revisions made under clause (ii), include such information for such biological product. Within 30 days of providing any subsequent or supplemental list of patents to any subsequent subsection (k) applicant under subsection (l)(3)(A) or (l)(7), the reference product sponsor shall update the information provided to the Secretary under this clause with any additional patents from such subsequent or supplemental list and their corresponding expiry dates. | |||
| (A)(iv) | (iv) Listing of exclusivities | (iv) Listing of exclusivities | ||
| For each biological product included on the list published under this subparagraph, the Secretary shall specify each exclusivity period under paragraph (6) or paragraph (7) for which the Secretary has determined such biological product to be eligible and that has not concluded | For each biological product included on the list published under this subparagraph, the Secretary shall [inserted: determine any applicable exclusivity period under paragraph (6) or (7), and shall ]specify each exclusivity period under paragraph (6) or paragraph (7) for which the Secretary has determined such biological product to be eligible and that has not concluded[inserted: , as follows:] | |||
| (A)(iv)(I) | (I) [inserted: Exclusivity for first interchangeable biological products.—] | |||
| (A)(iv)(I)(aa) | (aa) [inserted: Products licensed on or after the date of enactment.—] | |||
| [inserted: With respect to a biological product licensed under this subsection on or after the date of enactment of the Medication Competition Act, the Secretary shall include on the list published under this subparagraph any applicable exclusivity period under paragraph (6), not later than 30 days after the earliest date on which an expiration date of such an exclusivity period can be known pursuant to paragraph (6).] | ||||
| (A)(iv)(I)(bb) | (bb) [inserted: Products licensed before the date of enactment.—] | |||
| [inserted: With respect to a biological product licensed under this subsection before the date of enactment of the Medication Competition Act, the Secretary shall include on the list published under this subparagraph any applicable exclusivity period under paragraph (6), not later than 30 days after the later of such date of enactment or the earliest date on which an expiration date of such an exclusivity period can be known pursuant to paragraph (6).] | ||||
| (A)(iv)(II) | (II) [inserted: Exclusivity for reference products.—] | |||
| (A)(iv)(II)(aa) | (aa) [inserted: Products licensed on or after the date of enactment.—] | |||
| [inserted: With respect to a biological product licensed under subsection (a) on or after the date of enactment of the Medication Competition Act, the Secretary shall include on the list published under this subparagraph the expiration date of any exclusivity period under paragraph (7), not later than 30 days after licensure of the biological product.] | ||||
| (A)(iv)(II)(bb) | (bb) [inserted: Products licensed before the date of enactment.—] | |||
| [inserted: With respect to any biological product licensed under subsection (a) before the date of enactment of the Medication Competition Act, the Secretary shall include on the list published under this subparagraph the expiration date of any exclusivity period under paragraph (7), not later than 2 years after such date of enactment.] | ||||
| (B) | (B) Revocation or suspension of license | (B) Revocation or suspension of license | ||
| If the license of a biological product is determined by the Secretary to have been revoked or suspended for safety, purity, or potency reasons, it may not be published in the list under subparagraph (A). If such revocation or suspension occurred after inclusion of such biological product in the list published under subparagraph (A), the reference product sponsor shall notify the Secretary that— | If the license of a biological product is determined by the Secretary to have been revoked or suspended for safety, purity, or potency reasons, it may not be published in the list under subparagraph (A). If such revocation or suspension occurred after inclusion of such biological product in the list published under subparagraph (A), the reference product sponsor shall notify the Secretary that— | |||
| (B)(i) | (i) | (i) | ||
| the biological product shall be immediately removed from such list for the same period as the revocation or suspension; and | the biological product shall be immediately removed from such list for the same period as the revocation or suspension; and | |||
Rest of § 262 unchanged